<DOC>
	<DOCNO>NCT00082069</DOCNO>
	<brief_summary>The vaccine give nose spray . Volunteers receive 3-dose vaccination dos space two week apart . Volunteers assign vaccination group base order enrollment consideration availability complete necessary vaccination follow-up visit .</brief_summary>
	<brief_title>Invaplex 50 Vaccine Dose-Ranging</brief_title>
	<detailed_description>This open-labeled dose escalate trial total 32 subject ( minimum 24 allowable ) receive one four intranasal Invaplex 50 vaccine dos accord follow chart : Test articles/dose Group / N* / Invaplex 50 A / 8 / 10 microgram B / 8 / 50 microgram C / 8 / 240 microgram D / 8 / 480 microgram *minimum 6 volunteers/group An interval less 7 day follow third ( final ) dose ( total 35 day initial dose low dose level next initial dose next high dose level ) separate volunteer group receive different dos . All volunteer receive three immunization . The first dosing time point Day 0 , second Day 14 ( +- one day ) , third Day 28 ( +- 2 day ) . Blood stool specimen collect interval examine systemic mucosal vaccine antigen-specific immune response . Vaccine safety actively monitor vaccination 28 day follow third vaccination dose .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Be good health . Smoker , stop smoke less one year ago Pregnant History chronic illness , : asthma , chronic sinusitis , chronic seasonal allergy ( hay fever ) Received vaccination Shigella exposure Shigella bacteria research study work laboratory Positive HIV , hepatitis B , hepatitis C blood test Using antidiarrheal , anticonstipation , antacid medication regular basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Shigella</keyword>
	<keyword>diarrhea</keyword>
</DOC>